[go: up one dir, main page]

AR065202A1 - Un producto farmaceutico - Google Patents

Un producto farmaceutico

Info

Publication number
AR065202A1
AR065202A1 ARP080100504A ARP080100504A AR065202A1 AR 065202 A1 AR065202 A1 AR 065202A1 AR P080100504 A ARP080100504 A AR P080100504A AR P080100504 A ARP080100504 A AR P080100504A AR 065202 A1 AR065202 A1 AR 065202A1
Authority
AR
Argentina
Prior art keywords
oxazol
ylmethyl
cyclohexyl
dimethyl
phenyl
Prior art date
Application number
ARP080100504A
Other languages
English (en)
Inventor
John Dixon
Harry Finch
Katherine Wiley
Original Assignee
Argenta Discovery Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argenta Discovery Ltd, Astrazeneca Ab filed Critical Argenta Discovery Ltd
Publication of AR065202A1 publication Critical patent/AR065202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Producto farmacéutico, kit o composicion que comprende un primer ingrediente activo que es un antagonista del receptor muscarínico seleccionado y un segundo ingrediente activo que es un agonista de beta2-adrenoceptor, para uso en el tratamiento de enfermedades respiratorias como la enfermedad pulmonar obstructiva cronica y el asma. Reivindicacion 1:Un producto farmacéutico que comprende, en combinacion, un primer ingrediente activo que es un antagonista muscarínico seleccionado de: sal de [2-((S)-Ciclohexil-hidroxi-fenil-metil)-oxazol-5-ilmetil]-dimetil-(3-fenoxi-propil)-amonio, sal de [2-((R)-Ciclohexil-hidroxi-fenil-metil)-oxazol-5-ilmetil]-dimetil -(3-fenoxi-propil)-amonio, sal de (2-((R)-Ciclohexil-hidroxi-fenil-metil)-oxazol-5- ilmetil]-dimetil-(2-fenetiloxi-etil)-amonio, sal de [2-((R)-Ciclohexil-hidroxi-fenil-metil)-oxazol-5-ilmetil-[3-(3,4-dicloro-fenoxi)-propil] dimetil-amonio, sal de (2-((R)-Ciclohexil-hidroxi-fenil-metil)-oxazol-5-ilmetil]-[2-(3,4-dicloro-benciloxi)- etil]-dimetil-amonio y sal de [2-(4-Cloro-benciloxi)-etil]-[2-((R)-Ciclohexil hidroxi-fenil-metil)-oxazol-5-ilmetil]-dimetil-amonio; y un segundo ingrediente activo que es un agonista de beta2-adrenoceptor.
ARP080100504A 2007-02-07 2008-02-06 Un producto farmaceutico AR065202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0702385.6A GB0702385D0 (en) 2007-02-07 2007-02-07 New combination

Publications (1)

Publication Number Publication Date
AR065202A1 true AR065202A1 (es) 2009-05-20

Family

ID=37898913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100504A AR065202A1 (es) 2007-02-07 2008-02-06 Un producto farmaceutico

Country Status (18)

Country Link
US (1) US20110046191A1 (es)
EP (1) EP2124941A1 (es)
JP (1) JP5337054B2 (es)
KR (1) KR20090114389A (es)
CN (2) CN101678005B (es)
AR (1) AR065202A1 (es)
AU (1) AU2008212649B2 (es)
BR (1) BRPI0806966A2 (es)
CA (1) CA2675718A1 (es)
CL (1) CL2008000380A1 (es)
GB (1) GB0702385D0 (es)
MX (1) MX2009008363A (es)
PE (1) PE20081751A1 (es)
RU (1) RU2460527C2 (es)
TW (1) TW200901986A (es)
UA (1) UA99604C2 (es)
WO (1) WO2008096126A1 (es)
ZA (1) ZA200905106B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
BRPI0822693A2 (pt) 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
UY31920A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) * 2008-12-18 2009-01-28 Astrazeneca Ab New combination
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3646870A1 (en) 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
CN109896934A (zh) * 2019-03-08 2019-06-18 山东省药学科学院 一种高纯度2-苄氧基溴乙烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053748T3 (es) * 1987-09-10 1994-08-01 Merck Sharp & Dohme Oxazoles y tiazoles para el tratamiento de la demencia senil.
FR2675142B1 (fr) * 1991-04-10 1993-06-25 Roussel Uclaf Nouveaux derives de l'acide alpha-methylene 4-[(phenoxy) methyl] 5-thiazolacetique, leur procede de preparation et les intermediaires de ce procede et leur application a titre de fongicides.
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
SE9902935D0 (sv) * 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
US7332175B2 (en) * 2003-05-27 2008-02-19 Boehringer Ingelheim International Gmbh Long-acting drug combinations for the treatment of respiratory complaints
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7745621B2 (en) * 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses

Also Published As

Publication number Publication date
TW200901986A (en) 2009-01-16
GB0702385D0 (en) 2007-03-21
ZA200905106B (en) 2010-05-26
BRPI0806966A2 (pt) 2014-04-08
CN101636390A (zh) 2010-01-27
US20110046191A1 (en) 2011-02-24
PE20081751A1 (es) 2008-12-27
CN101636390B (zh) 2013-06-12
AU2008212649B2 (en) 2011-05-19
JP5337054B2 (ja) 2013-11-06
WO2008096126A1 (en) 2008-08-14
MX2009008363A (es) 2009-08-20
UA99604C2 (ru) 2012-09-10
CN101678005A (zh) 2010-03-24
RU2009133261A (ru) 2011-03-20
AU2008212649A1 (en) 2008-08-14
CA2675718A1 (en) 2008-07-14
RU2460527C2 (ru) 2012-09-10
KR20090114389A (ko) 2009-11-03
EP2124941A1 (en) 2009-12-02
JP2010518059A (ja) 2010-05-27
CN101678005B (zh) 2012-10-31
CL2008000380A1 (es) 2008-08-18

Similar Documents

Publication Publication Date Title
AR065202A1 (es) Un producto farmaceutico
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
CL2007003755A1 (es) Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BRPI1011508A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio pulmonar em um paciente ou população de pacientes, e para dispensação respiratória de um agente ativo a um paciente, e, inalador de dose medida.
CL2012003171A1 (es) Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias.
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
BR112012029653A2 (pt) formulação tópica para um inibidor jak
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
JP2009541443A5 (es)
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
BRPI0816320A2 (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
WO2010109482A3 (en) Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
CR10305A (es) "derivados sustituidos de cromanol y su uso.
CL2009000491A1 (es) Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma.
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre

Legal Events

Date Code Title Description
FB Suspension of granting procedure